Advancements in Alzheimer's Disease Therapy: The Role of Anti-Amyloid Monoclonal Antibodies - A Literature Review
DOI:
https://doi.org/10.12775/JEHS.2025.79.58362Keywords
Alzheimer's disease, anti-amyloid monoclonal antibodies, aducanumab, lecanemab, donanemab, ARIAAbstract
Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and neuronal damage. Anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab, represent the first disease-modifying therapies for Alzheimer’s disease, specifically targeting amyloid-β plaques, a hallmark of the disease. This review examines the pathogenesis of Alzheimer’s disease, the mechanism of action of these anti-amyloid therapies, and their potential benefits and associated risks, particularly amyloid-related imaging abnormalities (ARIA). While these therapies have demonstrated statistically significant efficacy in reducing amyloid plaques and decelerating cognitive decline, further research is required to confirm their long-term clinical benefits and establish a precise safety profile. Nonetheless, the approval of these monoclonal antibodies constitutes a significant advancement and potentially heralds the beginning of a new era in the treatment of Alzheimer’s disease.
References
1. 2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024;20(5):3708-3821. doi:10.1002/alz.13809
2. World Health Organization (WHO) Dementia. Key facts. https://www.who.int/news-room/fact-sheets/detail/dementia.
3. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-1590. doi:10.1016/S0140-6736(20)32205-4
4. Byard RW, Langlois NEI. Wandering Dementia-A Syndrome with Forensic Implications. J Forensic Sci. 2019;64(2):443-445. doi:10.1111/1556-4029.13885
5. Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. BioDrugs. 2024;38(1):5-22. doi:10.1007/s40259-023-00633-2
6. Belder CRS, Schott JM, Fox NC. Preparing for disease-modifying therapies in Alzheimer's disease. Lancet Neurol. 2023;22(9):782-783. doi:10.1016/S1474-4422(23)00274-0
7. Aducanumab Discontinued as an Alzheimer’s Treatment https://www.alz.org/alzheimers-dementia/treatments/aducanumab
8. Wang Q, Chen S, Wang J, Shang H, Chen X. Advancements in Pharmacological Treatment of Alzheimer's Disease: The Advent of Disease-Modifying Therapies (DMTs). Brain Sci. 2024;14(10):990. Published 2024 Sep 29. doi:10.3390/brainsci14100990
9. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(8):759-767. doi:10.1093/jnen/60.8.759
10. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019;14:5541-5554. Published 2019 Jul 19. doi:10.2147/IJN.S200490
11. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics [published correction appears in Science 2002 Sep 27;297(5590):2209]. Science. 2002;297(5580):353-356. doi:10.1126/science.1072994
12. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752-758. doi:10.1056/NEJM199603213341202
13. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches [published correction appears in Lancet Neurol. 2021 Feb;20(2):e2. doi: 10.1016/S1474-4422(21)00004-1]. Lancet Neurol. 2021;20(1):68-80. doi:10.1016/S1474-4422(20)30412-9
14. Li Y, Laws SM, Miles LA, et al. Genomics of Alzheimer's disease implicates the innate and adaptive immune systems. Cell Mol Life Sci. 2021;78(23):7397-7426. doi:10.1007/s00018-021-03986-5
15. Chen JX, Yan SS. Role of mitochondrial amyloid-beta in Alzheimer's disease. J Alzheimers Dis. 2010;20 Suppl 2:S569-S578. doi:10.3233/JAD-2010-100357
16. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet. 2010;19(R1):R12-R20. doi:10.1093/hmg/ddq160
17. Perneczky R, Dom G, Chan A, Falkai P, Bassetti C. Anti-amyloid antibody treatments for Alzheimer's disease. Eur J Neurol. 2024;31(2):e16049. doi:10.1111/ene.16049
18. Söderberg L, Johannesson M, Nygren P, et al. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics. 2023;20(1):195-206. doi:10.1007/s13311-022-01308-6
19. Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD. Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review. Health Psychol Res. 2022;10(1):31925. Published 2022 Jan 30. doi:10.52965/001c.31925
20. Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537(7618):50-56. doi:10.1038/nature19323
21. Arndt JW, Qian F, Smith BA, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018;8(1):6412. Published 2018 Apr 23. doi:10.1038/s41598-018-24501-0
22. FDA’s Decision to Approve New Treatment for Alzheimer’s Disease
https://www.fda.gov/drugs/our-perspective/fdas-decision-approve-new-treatment-alzheimers-disease
23. Dhillon S. Aducanumab: First Approval [published correction appears in Drugs. 2021 Sep;81(14):1701. doi: 10.1007/s40265-021-01590-2]. Drugs. 2021;81(12):1437-1443. doi:10.1007/s40265-021-01569-z
24. Greenberg SM, Cordonnier C, Schneider JA, et al. Off-label use of aducanumab for cerebral amyloid angiopathy. Lancet Neurol. 2021;20(8):596-597. doi:10.1016/S1474-4422(21)00213-1
25. Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021;8(4):398-410. doi:10.14283/jpad.2021.41
26. Cummings J, Rabinovici GD, Atri A, et al. Aducanumab: Appropriate Use Recommendations Update. J Prev Alzheimers Dis. 2022;9(2):221-230. doi:10.14283/jpad.2022.34
27. Salloway S, Chalkias S, Barkhof F, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2022;79(1):13-21. doi:10.1001/jamaneurol.2021.4161
28. Padda IS, Parmar M. Aducanumab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 26, 2024.
29. Englund H, Sehlin D, Johansson AS, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103(1):334-345. doi:10.1111/j.1471-4159.2007.04759.x
30. Kane M. Lecanemab Therapy and APOE Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, eds. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); August 12, 2024.
31. FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment
32. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377. doi:10.14283/jpad.2023.30
33. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
34. LEQEMBI- lecanemab injection, solution. Eisai Inc., Nutley, NJ 07110, U.S. License No. 1862; 2024
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975.
35. Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146(11):4414-4424. doi:10.1093/brain/awad188
36. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
37. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239
38. FDA approves treatment for adults with Alzheimer’s disease
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease
39. KISUNLA- donanemab-azbt injection, solution. Eli Lilly and Company, Indianapolis, IN 46285, USA, US License No. 1891; 2024
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=190352d4-ef62-4679-b4fa-e846e2766afa
40. Høilund-Carlsen PF, Alavi A, Barrio JR, et al. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit. Ageing Res Rev. 2024;99:102348. doi:10.1016/j.arr.2024.102348
41. Beshir SA, Hussain N, Menon VB, Al Haddad AHI, Al Zeer RAK, Elnour AA. Advancements and Challenges in Antiamyloid Therapy for Alzheimer's Disease: A Comprehensive Review. Int J Alzheimers Dis. 2024;2024:2052142. Published 2024 Jul 23. doi:10.1155/2024/2052142
42. Cummings J, Lee G, Nahed P, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8(1):e12295. Published 2022 May 4. doi:10.1002/trc2.12295
43. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263. doi:10.1016/S0140-6736(15)60461-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Agnieszka Skoczeń, Natalia Rutecka, Błażej Kaczmarek, Agata Kuśnierz-Gibała, Adrian Kruk, Michał Kulesza, Weronika Wawrzynów, Martyna Miłoś, Aleksandra Dorosz, Magdalena Maria Jakubowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 230
Number of citations: 0
